Literature DB >> 24128411

Maternal and fetal alternative complement pathway activation in early severe preeclampsia.

M Camille Hoffman1, Kristen K Rumer, Anita Kramer, Anne M Lynch, Virginia D Winn.   

Abstract

PROBLEM: We sought to determine whether alternative complement activation fragment Bb (Bb) levels are elevated in the maternal, fetal, and placental blood in cases of severe preeclampsia (PE) compared with normotensive controls. METHOD OF STUDY: This was a cross-sectional study of women admitted at ≥24 weeks gestation with or without severe PE. Maternal plasma was collected at the time of enrollment. Umbilical venous cord and intervillous space blood were collected at delivery. Plasma Bb levels were assessed using ELISA. Bb levels were compared between cases and controls.
RESULTS: Median Bb levels were higher in the maternal plasma of severe PE subjects (n = 24) than in controls (n = 20), 1.45 ± 1.03 versus 0.65 ± 0.23 μg/mL, P < 0.001. In umbilical venous plasma, Bb levels were higher in severe PE subjects (n = 15) compared with controls (n = 15), 2.48 ± 1.40 versus 1.01 ± 0.57 μg/mL, P = 0.01.
CONCLUSION: Activation fragment Bb is increased in the maternal and umbilical venous blood of cases of severe PE when compared with normotensive controls. These data provide support for alternative complement pathway involvement in the pathogenesis of severe PE and demonstrate that alternative complement activation occurs not only in the maternal but also in the fetal compartment.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Activation fragment Bb; alternative complement pathway; severe Preeclampsia

Mesh:

Substances:

Year:  2013        PMID: 24128411      PMCID: PMC4067768          DOI: 10.1111/aji.12162

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  21 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

3.  Specificity of EIA immunoassay for complement factor Bb testing.

Authors:  Igor Y Pavlov; Nikol De Forest; Julio C Delgado
Journal:  Clin Lab       Date:  2011       Impact factor: 1.138

4.  Increased systemic activation of neutrophils but not complement in preeclampsia.

Authors:  J R Mellembakken; K Høgåsen; T E Mollnes; C E Hack; T Abyholm; V Videm
Journal:  Obstet Gynecol       Date:  2001-03       Impact factor: 7.661

5.  HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: onset at < or =28.0 weeks' gestation.

Authors:  B Haddad; J R Barton; J C Livingston; R Chahine; B M Sibai
Journal:  Am J Obstet Gynecol       Date:  2000-12       Impact factor: 8.661

6.  Activation of the alternative pathway of complement is a feature of pre-term parturition but not of spontaneous labor at term.

Authors:  Edi Vaisbuch; Roberto Romero; Offer Erez; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Eleazar Soto; Zhong Dong; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Giovanna Ogge; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  Am J Reprod Immunol       Date:  2010-02-12       Impact factor: 3.886

7.  Placental stress and pre-eclampsia: a revised view.

Authors:  C W G Redman; I L Sargent
Journal:  Placenta       Date:  2009-01-12       Impact factor: 3.481

8.  The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.

Authors:  A M Lynch; J R Murphy; R S Gibbs; R J Levine; P C Giclas; J E Salmon; V M Holers
Journal:  BJOG       Date:  2010-01-14       Impact factor: 6.531

Review 9.  Expectant management in pregnancies with severe pre-eclampsia.

Authors:  Bassam Haddad; Baha M Sibai
Journal:  Semin Perinatol       Date:  2009-06       Impact factor: 3.300

10.  Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.

Authors:  V Michael Holers; Guillermina Girardi; Lian Mo; Joel M Guthridge; Hector Molina; Silvia S Pierangeli; Ricardo Espinola; Liu E Xiaowei; Dailing Mao; Christopher G Vialpando; Jane E Salmon
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  20 in total

1.  The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.

Authors:  Anne M Lynch; Brandie D Wagner; Patricia C Giclas; Nancy A West; Ronald S Gibbs; V Michael Holers
Journal:  Am J Reprod Immunol       Date:  2015-10-29       Impact factor: 3.886

2.  Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.

Authors:  Yoshiyasu Ueda; Imran Mohammed; Delu Song; Damodar Gullipalli; Lin Zhou; Sayaka Sato; Yuan Wang; Shuchi Gupta; Zhongjian Cheng; Hong Wang; Jialing Bao; Yingying Mao; Lawrence Brass; X Long Zheng; Takashi Miwa; Matthew Palmer; Joshua Dunaief; Wen-Chao Song
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

3.  Complement factor B activation in patients with preeclampsia.

Authors:  Ivan Velickovic; Mudar Dalloul; Karen A Wong; Olufunke Bakare; Franz Schweis; Maya Garala; Amit Alam; Giorgio Medranda; Jovana Lekovic; Waqas Shuaib; Andreas Tedjasukmana; Perry Little; Daniel Hanono; Ruvini Wijetilaka; Jeremy Weedon; Jun Lin; Roulhac d'Arby Toledano; Ming Zhang
Journal:  J Reprod Immunol       Date:  2015-01-03       Impact factor: 4.054

4.  Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia.

Authors:  Layan Alrahmani; Maria L Gonzalez Suarez; Margot A Cousin; Ann M Moyer; Maria Alice V Willrich; Wendy M White; Myra J Wick; Linda J Tostrud; Kavita Narang; Vesna D Garovic
Journal:  Kidney360       Date:  2021-06-30

5.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

Authors:  Mimi Y Kim; Marta M Guerra; Elianna Kaplowitz; Carl A Laskin; Michelle Petri; D Ware Branch; Michael D Lockshin; Lisa R Sammaritano; Joan T Merrill; T Flint Porter; Allen Sawitzke; Anne M Lynch; Jill P Buyon; Jane E Salmon
Journal:  Ann Rheum Dis       Date:  2018-01-25       Impact factor: 19.103

Review 6.  The Complement Alternative Pathway and Preeclampsia.

Authors:  Layan Alrahmani; Maria Alice V Willrich
Journal:  Curr Hypertens Rep       Date:  2018-05-01       Impact factor: 5.369

Review 7.  Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.

Authors:  Ai-Ris Y Collier; Laura A Smith; S Ananth Karumanchi
Journal:  Hum Immunol       Date:  2021-02-05       Impact factor: 2.850

8.  Genetic analysis of membrane cofactor protein (CD46) of the complement system in women with and without preeclamptic pregnancies.

Authors:  A Inkeri Lokki; Tia Aalto-Viljakainen; Seppo Meri; Hannele Laivuori
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

9.  Preeclampsia is Characterized by Fetal NK Cell Activation and a Reduction in Regulatory T Cells.

Authors:  Andrea I Loewendorf; Tina A Nguyen; Maria N Yesayan; Daniel A Kahn
Journal:  Am J Reprod Immunol       Date:  2015-05-10       Impact factor: 3.886

10.  Serum Adipsin Levels throughout Normal Pregnancy and Preeclampsia.

Authors:  Natalia E Poveda; María F Garcés; Carlos E Ruiz-Linares; Diana Varón; Sergio Valderrama; Elizabeth Sanchez; Adriana Castiblanco-Cortes; Yessica Agudelo-Zapata; Héctor Fabio Sandoval-Alzate; Luis G Leal; Edith Ángel-Müller; Ariel I Ruíz-Parra; Angélica M González-Clavijo; Carlos Diéguez; Rubén Nogueiras; Jorge E Caminos
Journal:  Sci Rep       Date:  2016-02-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.